From OrbiMed Asia
Vivimed Labs has signed definitive agreements and received funds to facilitate additional investment of USD 7.5 million (follow on of USD 42.5 million invested in September 2017) by OrbiMed Asia into the Company's subsidiary Vivimed Labs (Mascarene), the holding entitiy of the Company's API business.Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)